Genmab shares hit 3-year high after blood cancer drug trial results
Genmab and AbbVie said on Monday their blood cancer drug combination cut risk of progression and death in late-stage study by 51% compared with R-CHOP alone, analysts at Jefferies called "impressive" and beating expectations of around 40%.